During her more than 30 years in the pharmaceutical industry, Ms. Lurker has driven scientific and commercial innovation across both public and private companies, from start-ups to the Fortune 500, to bring innovative therapies and diagnostic solutions to patients.
Ms. Lurker joined EyePoint in 2016 as President and CEO and served in this position for seven years before transitioning to her role as Executive-Vice Chair of the Board of Directors. Prior to joining EyePoint, Ms. Lurker was President, CEO, and Board Director of PDI, Inc., a NASDAQ-listed healthcare commercialization company, which sold to Publicis Health. Before joining PDI, she was Senior VP and Chief Marketing Officer at Novartis Pharmaceuticals. She also served as President and CEO of ImpactRx, Inc., a privately held healthcare information company. Prior to ImpactRx, Ms. Lurker was Group VP, Global Primary Care Products, for Pharmacia Corporation, and a member of Pharmacia’s US Executive Management Committee. She began her career as a Senior Medical Representative at Bristol Myers Squibb, where she quickly rose to Senior Director of Worldwide Cardiovascular Franchise Management, overseeing numerous successful drug launches.
Ms. Lurker currently serves on the Board of Directors of Eyepoint Pharmaceuticals and Altasciences, LLC. She also sits on Advisory Boards for Novo Holdings, Stanford Medicine Master of Science in Translational Research and Applied Medicine. She has previously held positions on the Boards of Cancer Treatment Centers of America, Mallinckrodt Pharmaceuticals, Auxilium Pharmaceuticals, PDI, Elan Pharmaceuticals, Conjuchem, and ImpactRx.
Ms. Lurker holds a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville. Dedicating her career to maximizing the potential of science to improve the lives of patients, Ms. Lurker is passionate about supporting the future of STEM and engaging with the critical thinkers and innovators of tomorrow.